Participants using Tirzepatide achieved a 15–25% reduction in body weight within six months, depending on the dosage.
In contrast, those who did not receive Tirzepatide experienced an average weight loss of only 3%.*
Tirzepatide continues to show promise as a powerful tool for weight management.
*Tirzepatide Once Weekly for the Treatment of Obesity. Ania M. Jastreboff, M.D., Ph.D., Louis J. Aronne, M.D. et al. Published June 4, 2022.
Tirzepatide is a dual agonist for GIP (glucose-dependent insulinotropic peptide) and GLP-1 (glucagon-like peptide-1), offering multiple benefits:
Blood Sugar Control: Helps regulate blood glucose levels.
Appetite Suppression: Delays digestion to reduce hunger.
Weight Loss Support: Encourages significant weight reduction.
As an agonist, Tirzepatide activates specific receptors to trigger a response. By targeting GIP and GLP-1 receptors, it enhances insulin secretion, supporting effective blood sugar management and weight loss.
Struggling to Achieve Your Weight Loss Goals?
Weight management isn’t just about calorie intake—other factors may be influencing your progress.
Conditions such as hormone imbalances, undiagnosed thyroid disorders, or PCOS can make weight loss challenging, no matter your efforts.
At Blain Wellness, we screen for underlying conditions that affect weight and create personalized, comprehensive weight loss plans. Many patients achieve success with GLP-1 agonists like Tirzepatide, combined with tailored treatments, diet, exercise, and supplements to meet their unique needs.
This compounded semaglutide/tirzepatide offered uses a different formulation or delivery system than FDA-approved semaglutide/tirzepatide. Disclaimer: Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. These medications may be prescribed by a licensed provider when clinically appropriate and prepared by a licensed compounding pharmacy.